Table 1.
Demographic, MRS and Segmentation Data for PIGD, TD, and control subjects
| PIGD | TD | Controls | P Value | |
|---|---|---|---|---|
| No.(female/male) | 13(8/5) | 9(6/3) | 16(9/7) | 0.789 |
| Age, y(mean ± SD) | 59.8±8.4 | 58.8±7.7 | 66±9.9 | 0.123 |
| Duration, y(mean ± SD) | 3.3±1.7 | 3.8±3.4 | --- | 0.582 |
| H-Y stage | 2.2±0.3 | 2.1±0.4 | --- | 0.206 |
| UPDRS (part III) | 30.2±7.7 | 32.1±9.9 | --- | 0.614 |
| GABA+ levels (IU) | 1.36±0.18 | 1.15±0.16 | 1.56±0.23 | 0.000a |
| Cr levels (IU) | 7.54±1.30 | 7.05±0.87 | 8.87±1.41 | 0.008a |
| GABA+ fitting errors (%) | 4.93±1.31 | 6.00±1.81 | 5.57±1.24 | 0.213 |
| GM/ (GM+WM) | 0.45±0.04 | 0.48±0.04 | 0.48±0.04 | 0.284 |
| CSF (%) | 5.7±1.7 | 6.4±1.6 | 5.0±1.5 | 0.214 |
H-Ystage = the Hoehn and Yahr stage; UPDRS = Unified Parkinson’s disease rating scale; SD = standard deviation; GM = gray matter; WM = white matter; CSF = cerebrospinal fluid; IU= institutional units.
a
Significant differences between groups are tested by analysis of covariance, adjusting for GM / (GM + WM+CSF) with P < 0.05 accepted as significant.